We found that primary glioma patients with higher-than-median expression levels of either SOCS1, SOCS3 or RNF7 had an unfavorable prognosis compared to those with lower-than-median expression levels (P < 0.0001) (Figure 5). This evidence concerns the gene SOCS1 and central nervous system cancer.